Background. This study aimed to examine the therapeutic effect and prognostic indicators of pegylated interferon (PEG-IFN) and ribavirin (RBV) combination therapy in thrombocytopenic patients with chronic hepatitis C, hepatitis C virus (HCV)-related cirrhosis, and those who underwent splenectomy or partial splenic embolization (PSE). He was prescribed a treatment of ribavirin and pegintron. He was not monitored until the fourth week when he had spontaneous bleeding in his eyes and as a result has permanent eye damage. During the therapy, the platelet count remained above 8.0 × 10 4 /μl for about 9 months. In January 2012, the platelet count was 6.8 × 10 4 /μl. In February 2012, the 44th week from the beginning of the treatment, a sudden decrease in the platelet count to 0.8 × 10 4 /μl was observed. Ribavirin tablets in combination with peginterferon alfa-2a are indicated for the treatment of patients 5 years of age and older with chronic hepatitis C (CHC) virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Summary. Platelet count decreased is found among people who take Ribavirin, especially for people who are male, 50-59 old , have been taking the drug for 1 - 6 months, also take medication Pegasys, and have Preventive health care. Background. Baseline low platelet count ( 150,000/μL) increases the risk of on-treatment severe thrombocytopenia (platelet count 50,000/μL) in patients with chronic hepatitis C (CHC) undergoing antiviral therapy, which may interrupt treatment. Changes in platelet counts during treatment with peginterferon alfa and ribavirin of all patients. Platelet counts below 150,000/μl were observed during 1600 visits in 251 patients (78.2%) and 135 patients (42.1%) developed a platelet count below 100,000/μl in 733 visits. The median (Q1-Q3) pretreatment platelet count was 58,000 (49,000-65,000) cells/mm(3) in the platelet ≤70,000 group and 129,000 (102,500-166,000) cells/mm(3) in the platelet 70,000 group (p 0.0001). Seventeen (28 %) subjects of the platelet ≤70,000 group and 71 (33 %) patients of the platelet 70,000 group achieved SVR (p = 0.4). Only 2 (3.2 %) patients in the platelet ≤70,000 group. Treatment with intravenous immunoglobulin resulted in a good ( 200×10 9 /L) but transient rise in platelet count after the first infusion, but was subsequently less effective. Ribavirin is not primarily responsible for a low platelet count. Ribavirin causes the premature breakdown of red blood cells which results in the anemia which so often afflicts us during treatment. Ribavirin causes the premature breakdown of red blood cells which results in the anemia which so often afflicts us during treatment.